



OXYGENTA PHARMACEUTICAL LIMITED

(Subsidiary of Virupaksha Organics Limited)

Regd. Office: Survey No.252/1, Aroor village, Sadasivapet Mandal, Medak District, Medak, Telangana, 502291, India.

Corp. Office: Level-I, Plot No. B1 & B2, IDA Gandhinagar, Kukatpally, Hyderabad-500037, Telangana, India.

Phone No. 040-23355938. CIN: L24110TG1990PLC012038

Email IDs: md@oxygentapharma.com, cs@oxygentapharma.com, website: www.oxygentapharma.com

STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. in Lakhs)

S. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	1,424.61	1,530.37	1,475.45	2,954.99	2,739.78	11,060.77
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(643.78)	(813.62)	(277.33)	(1,457.40)	(559.03)	(1,408.14)
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(643.78)	(814.80)	(277.33)	(1,458.79)	(559.03)	(1,435.14)
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(493.04)	(610.61)	(285.38)	(1,103.87)	(421.71)	(1,029.65)
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	(493.04)	(610.61)	(285.38)	(1,103.87)	(421.71)	(1,040.38)
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	3,698.35	3,698.35	3,548.35	3,698.35	3,548.35	3,698.35
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year ended)	-	-	-	-	-	-
8	Earnings Per Share (of Rs.10/- each) (Not Annualised):						
	a) Basic	(1.33)	(1.65)	(0.81)	(2.98)	(1.20)	(2.86)
	b) Diluted	(1.33)	(1.65)	(0.78)	(2.98)	(1.15)	(2.86)

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 7th November, 2025 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- Total Turnover for the current quarter reported Rs.1430.23 Lakhs compared to Rs.1400.52 for the corresponding quarter of the previous year.
- The Loss before tax for the current quarter is Rs.643.78 Lakhs compared to Loss Before tax of Rs.277.33 Lakhs for the corresponding quarter of the previous year.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.
- The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting. Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.



By and on behalf of the Board of Directors of
Oxygenta Pharmaceutical Limited

Sd/-

BALASUBBA REDDY MAMILLA

Whole Time Director

DIN:01998852

Place : Hyderabad
Date : 07.11.2025

నినాదం

నిఖార్సేన జర్నలిజం

అదివారం, నవంబర్ 9, 2025

సంపుటి - 22

సంచిక 48

వెల - 7

పేజీలు - 12 - 8

Published from Hyderabad, Vijayawada Circulated from TS and AP. Hyderabad, Karimnagar, Khammam, Mahabubnagar, Nalgonda, Nizamabad, Warangal, Vijayawada, Guntur, Ongole, Nellore, Tirupathi, Kadapa, Ananthapur, Kurnool, Tadepalligudem, Rajahmundry, Visakhapatnam, Srikakulam



OXYGENTA PHARMACEUTICAL LIMITED (Subsidiary of Virupaksha Organics Limited)

Regd. Office: Survey No.252/1, Aroor village, Sadasivapet Mandal, Medak District, Medak, Telangana, 502291, India.

Corp.Office: Level-I, Plot No. B1 & B2, IDA Gandhinagar, Kukatpally, Hyderabad-500037, Telangana, India.

Phone No. 040-23355938. CIN: L24110TG1990PLC012038

Email IDs: md@oxygentapharma.com, cs@oxygentapharma.com, website: www.oxygentapharma.com

STATEMENT OF UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2025

(Rs. in Lakhs)

S. No	Particulars	Quarter Ended			Half Year Ended		Year Ended
		30-09-2025	30-06-2025	30-09-2024	30-09-2025	30-09-2024	31-03-2025
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from Operations	1,424.61	1,530.37	1,475.45	2,954.99	2,739.78	11,060.77
2	Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	(643.78)	(813.62)	(277.33)	(1,457.40)	(559.03)	(1,408.14)
3	Net Profit / (Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	(643.78)	(814.80)	(277.33)	(1,458.79)	(559.03)	(1,435.14)
4	Net Profit / (Loss) for the period after Tax (after Exceptional and/or Extraordinary items)	(493.04)	(610.61)	(285.38)	(1,103.87)	(421.71)	(1,029.65)
5	Total Comprehensive Income [Comprising Profit after tax and Other Comprehensive Income (after tax)]	(493.04)	(610.61)	(285.38)	(1,103.87)	(421.71)	(1,040.38)
6	Paid up Equity Share Capital (Rs.10/- Per Equity Share)	3,698.35	3,698.35	3,548.35	3,698.35	3,548.35	3,698.35
7	Reserves (excluding Revaluation Reserve as shown in the Balance Sheet of previous year ended)	-	-	-	-	-	-
8	Earnings Per Share (of Rs.10/- each) (Not Annualised):						
	a) Basic	(1.33)	(1.65)	(0.81)	(2.98)	(1.20)	(2.86)
	b) Diluted	(1.33)	(1.65)	(0.78)	(2.98)	(1.15)	(2.86)

- The above results have been reviewed by the Audit committee and approved by the Board of Directors at its meeting held on 7th November, 2025 at Corporate office, Level-1 Plot No B1 and B2, IDA Gandhi Nagar, Balanagar Township Hyderabad
- The Statutory Auditors of the Company have carried out "Limited Review" of the above unaudited financial results and their Report has been placed before the Board at the said Meeting as required under Regulation 33 of SEBI (LODR) Regulations, 2015.
- The financial results of the company have been prepared in accordance with Indian Accounting Standards (Ind AS) notified under the companies (Indian Accounting standards) Rules, 2015 as amended by the companies (Indian Accounting standards) (Amendment) rules, 2016.
- The Entire operations of the Company relate to only one segment i.e Manufacturing of Pharmaceutical Products., Hence, segmental reporting as per IND AS-108 is not made.
- Total Turnover for the current quarter reported Rs.1430.23 Lakhs compared to Rs.1400.52 for the corresponding quarter of the previous year.
- The Loss before tax for the current quarter is Rs.643.78 Lakhs compared to Loss Before tax of Rs.277.33 Lakhs for the corresponding quarter of the previous year.
- Previous period/year figures have been regrouped and rearranged wherever necessary to facilitate comparison.
- The Company is actively working to complete the identification of its MSME creditors, though a few gaps remain in this process. To facilitate accurate identification, we have requested all suppliers to submit self-declaration forms confirming their MSME status. The Company is currently in the process of collecting these declarations from suppliers to enhance accuracy in reporting. Additionally, the Company has yet to implement a bill-to-bill adjustment process, which has posed challenges in preparing a precise aging schedule for its creditors. Addressing these outstanding issues remains a priority, and the Company is committed to achieving full compliance and transparency in its reporting.



By and on behalf of the Board of Directors of
Oxygenta Pharmaceutical Limited
Sd/-
BALASUBBA REDDY MAMILLA
Whole Time Director
DIN:01998852

Place : Hyderabad
Date : 07.11.2025